Monika Prylińska-Jaśkowiak | Immunology and Microbiology | Young Scientist Award

Published on by Forensic Scientist

Mrs. Monika Prylińska-Jaśkowiak | Immunology and Microbiology | Young Scientist Award

Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University | Poland

Mrs. Monika Prylińska-Jaśkowiak is an emerging clinician-scientist whose professional journey reflects a rare balance between medical practice, academic excellence, and translational research. She earned her Doctor of Medical Sciences degree from Collegium Medicum, Nicolaus Copernicus University in Toruń, where her doctoral research focused on the relationship between the gut microbiome and chronic fatigue syndrome, integrating clinical insight with advanced molecular and bioinformatic analyses. As a specialist pediatrician at the Voivodeship Children’s Hospital in Bydgoszcz, she combines her research background with everyday patient care and is currently pursuing specialization in pediatric rheumatology. Her scientific contributions include peer-reviewed publications such as The gut microbial composition is different in chronic fatigue syndrome than in healthy controls (Scientific Reports, 2025), and review papers in the Journal of Education, Health and Sport (2022), widely cited for summarizing current knowledge on CFS/ME and human gut microbiota. Mrs. Monika Prylińska-Jaśkowiak’s research interests encompass pediatric immunology, microbiome–immune interactions, and chronic inflammatory diseases, with a focus on precision diagnostics and targeted therapy development. Actively engaged in professional societies including the Polish Pediatric Society and the Polish Society of Vaccinology, she continues to expand her expertise through certified courses in resuscitation, vaccinology, and emergency pediatrics. Her commitment to continuous learning, clinical excellence, and evidence-based innovation exemplifies the spirit of a modern physician-scientist dedicated to improving child health and advancing medical science.

Profile: ORCID | LinkedIn

Featured Publications

• Prylińska, M., & Kożuchowski, M. (2022, September 28). The human gastrointestinal tract microbiota in health – current knowledge summary. Journal of Education, Health and Sport, 12(10). https://doi.org/10.12775/JEHS.2022.12.10.005

• Kożuchowski, M., & Prylińska, M. (2022, April 30). The proper functioning of the sense of smell and its disturbances on the example of COVID-19 infection. Journal of Education, Health and Sport, 12(4). https://doi.org/10.12775/JEHS.2022.12.04.026

Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Majid Taati Moghadam | Immunology and Microbiology | Best Researcher Award

Guilan University of Medical Sciences | Iran

Dr. Majid Taati Moghadam is a dedicated Medical Microbiologist and Antimicrobial Resistance Researcher based in Rasht, Iran. He specializes in microbial pathogenesis, antibiotic resistance mechanisms, bacteriophage therapy, and the connection between microbiota and neurodegenerative disorders. His multidisciplinary expertise extends across clinical microbiology, infectious disease prevention, and translational therapeutics, making him a leading figure in Iran’s microbiological research community.

Professional Profile

Scopus

Google Scholar

ORCID

Education

Dr. Majid Taati holds a Ph.D. in Medical Bacteriology from Iran University of Medical Sciences (2017–2022), where his research investigated the relationship between oral microbiome shifts and Alzheimer’s disease. He earned his Master’s degree in Medical Microbiology from Kerman University of Medical Sciences (2012–2015), focusing on carbapenem resistance genes in Klebsiella pneumoniae. His academic journey began with a Bachelor’s degree in Microbiology from Islamic Azad University, Lahijan Branch (2007–2012). Throughout his studies, he demonstrated a keen interest in antibiotic resistance, clinical diagnostics, and the molecular biology of pathogens.

Experience

Dr. Majid Taati has played key roles in over a dozen microbiological research projects across Iran. As both a principal investigator and main collaborator, he has contributed to studies on extended-spectrum beta-lactamase (ESBL) genes, resistance enzymes in E. coli, and the antimicrobial effects of plant extracts like Ephedra pachyclada. He has worked extensively on projects involving nosocomial infections, multidrug-resistant bacteria, and genetic analysis methods such as MLVA and HRM techniques. He also authored the textbook Essential Medical Microbiology in Persian, and presented his findings at several major Iranian congresses, including the International Microbiology Congress. His laboratory and academic experience bridges both applied research and educational leadership.

Research Interests

Dr. Majid Taati research focuses on antimicrobial resistance mechanisms, phage and endolysin therapy, bacterial biofilm inhibition, and engineered phage enzymes for resistant infections. He is also deeply involved in exploring the role of microbiota in neurological and neuropsychiatric disorders, especially Alzheimer’s disease. His studies aim to bridge clinical microbiology with therapeutic innovation addressing global health threats posed by superbugs like carbapenem- and colistin-resistant Gram-negative bacteria. His recent projects extend to wound healing biomaterials, phage protein therapies, and microbiome-based diagnostics, reflecting his broad and multidisciplinary scientific interests.

Awards

Recognized for his extensive research contributions, Dr. Majid Taati is a deserving nominee for the “Best Researcher Award” in medical microbiology and antimicrobial resistance. His scholarly excellence, particularly in phage therapy and resistance gene profiling, aligns well with the objectives of scientific bodies that honor groundbreaking research. With dozens of publications in top-tier journals and continuous involvement in nationally significant projects, he exemplifies leadership in translational microbiology and global infectious disease research.

Publications

  • Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
    Year: 2020
    Citations: 316

  • Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
    Year: 2020
    Citations: 311

  • How phages overcome the challenges of drug resistant bacteria in clinical infections
    Year: 2020
    Citations: 173

  • Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials
    Year: 2020
    Citations: 125

  • COVID-19 (Coronavirus disease 2019): a new coronavirus disease
    Year: 2020
    Citations: 108

  • Evaluation of Nano-curcumin effects on expression levels of virulence genes and biofilm production of multidrug-resistant Pseudomonas aeruginosa isolated from clinical samples
    Year: 2019
    Citations: 108

  • Bacteriophage as a novel therapeutic weapon for killing colistin-resistant multi-drug-resistant and extensively drug-resistant gram-negative bacteria
    Year: 2021
    Citations: 58

Conclusion

Dr. Majid Taati Moghaddam Ziabari has built an impressive career defined by scientific innovation, deep academic rigor, and a commitment to combating infectious diseases. His pioneering work in bacteriophage therapy and antimicrobial resistance not only advances microbiological science but also addresses some of the most urgent global health challenges. With his rich publication record, research leadership, and academic influence, he is a prime candidate for international recognition, especially the Best Researcher Award. His career serves as a model of excellence in translational research and academic impact.

Omur Baysal | Microbiology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Omur Baysal | Microbiology | Best Researcher Award

Mugla Sitki Kocman University | Turkey

Prof. Dr. Ömür Baysal is a tenured researcher in Molecular Microbiology at Muğla University (Turkey) and an Honorary Professor at the University of Worcester (UK). His work focuses on host-microbe interactions, molecular markers, biological control of pathogens, antibiotic resistance, and bioinformatics (genomics, proteomics, drug discovery). With an H-index of 20, he bridges lab research and computational biology.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  1. High-Impact Research Output

    • Extensive Publications: Over 35+ SCI/SCI-E indexed journal articles, demonstrating consistent contributions to molecular microbiology, plant-pathogen interactions, and bioinformatics.

    • Diverse Research Areas: Expertise spans host-microbe interactions, antibiotic resistance, biocontrol agents, drug discovery, and omics technologies (genomics, proteomics, metagenomics).

    • Recent High-Profile Works (2023-2024):

      • Anticancer Agents in Medical Chemistry (2024) – Machine learning & cancer research.

      • PLoS ONE (2021) – Computational analysis of SARS-CoV-2.

      • Frontiers in Oncology (2023) – Cold plasma therapy in cancer.

  2. International Collaborations & Recognition

    • Honorary Professorship (UK): Affiliation with the University of Worcester strengthens global research ties.

    • Sabbaticals & Invited Research Roles: Worked at USDA/USA, Volcani Center (Israel), CNR (Italy), CIRAD (France), indicating international recognition.

    • Multi-Country Co-Authorships: Collaborations with researchers from Germany, Israel, Italy, UK, Belarus, etc.

  3. Innovative Methodologies

    • Bioinformatics & AI Integration: Use of machine learning, molecular docking, RNA-seq, and metagenomics in pathogen studies.

    • Biocontrol & Sustainable Agriculture: Focus on biological control agents (Bacillus spp.) and host-induced gene silencing (HIGS).

    • Translational Research: Applied studies on drug discovery (HIV-1, breast cancer, SARS-CoV-2).

  4. Strong Academic Metrics

    • H-index: 20 | I-index: 31 (Google Scholar) – Reflects sustained citation impact.

    • Editorial Roles: Serves as a referee for Frontiers in Microbiology, PLOS ONE, Plant Disease (APS), etc.

Education 🎓

  • B.Sc. (1994): Plant Protection Engineering, Akdeniz University, Turkey.

  • M.Sc. (1997): Phytopathology, Akdeniz University.

  • Ph.D. (2001): Plant Pathology (Bacteriology), University of Göttingen, Germany.

  • Postdoc Training (2007–2014): Volcani Center (Israel), CNR Italy, CIRAD France, USDA/University of Florida (USA).

Experience 💼

  • Current Roles:

    • Professor, Molecular Microbiology & Bioinformatics, Muğla University.

    • Honorary Professor, Biosciences, University of Worcester (UK).

  • Expertise: Molecular diagnostics, biocontrol agents, recombinant DNA, protein-ligand docking, and whole-genome/RNA-seq analysis.

Research Interests On Microbiology 🔍

  • Host-microbe interactions

  • Antibiotic resistance mechanisms

  • Biological control of plant pathogens

  • Bioinformatics (genomics, metagenomics, drug discovery)

  • Enzyme enhancement via recombinant tech

Awards & Honors 🏆

  • High-impact publications (31+ SCI-indexed papers).

  • International collaborations (US, EU, Israel).

  • Editorial roles in Frontiers in Microbiology, PLoS ONE, Plant Pathology, etc.

Publications 📚

  • Title: Induction of defence‐related enzymes and resistance by the plant activator acibenzolar‐S‐methyl in tomato seedlings against bacterial canker caused by Clavibacter michiganensis
    Authors: Ö Baysal, EM Soylu, S Soylu
    Year: 2003
    Cited by: 227

  • Title: Induction of disease resistance by the plant activator, acibenzolar-S-methyl (ASM), against bacterial canker (Clavibacter michiganensis subsp. michiganensis) in tomato seedlings
    Authors: S Soylu, Ö Baysal, EM Soylu
    Year: 2003
    Cited by: 164

  • Title: An inhibitory effect of a new Bacillus subtilis strain (EU07) against Fusarium oxysporum f. sp. radicis-lycopersici
    Authors: Ö Baysal, M Çalışkan, Ö Yeşilova
    Year: 2008
    Cited by: 151

  • Title: A Proteomic Approach Provides New Insights into the Control of Soil-Borne Plant Pathogens by Bacillus Species
    Authors: Ö Baysal, D Lai, HH Xu, M Siragusa, M Çalışkan, F Carimi, JAT Da Silva, …
    Year: 2013
    Cited by: 124

  • Title: Molecular Characterization of Fusarium oxysporum f. melongenae by ISSR and RAPD Markers on Eggplant
    Authors: Ö Baysal, M Siragusa, E Gümrükcü, S Zengin, F Carimi, M Sajeva, …
    Year: 2010
    Cited by: 112

  • Title: Chemical composition and antifungal activity of the essential oil of Artemisia annua L. against foliar and soil-borne fungal pathogens
    Authors: EM Soylu, H Yiğitbaş, FM Tok, S Soylu, Ş Kurt, Ö Baysal, AD Kaya
    Year: 2005
    Cited by: 109

  • Title: Induction of oxidants in tomato leaves treated with DL-β-Amino butyric acid (BABA) and infected with Clavibacter michiganensis ssp. michiganensis
    Authors: Ö Baysal, YZ Gürsoy, H Örnek, A Duru
    Year: 2005
    Cited by: 108

  • Title: Acibenzolar-S-methyl induced resistance to Phytophthora capsici in pepper leaves
    Authors: O Baysal, C Turgut, G Mao
    Year: 2005
    Cited by: 75

  • Title: Extract of Hedera helix induces resistance on apple rootstock M26 similar to Acibenzolar-S-methyl against Fire Blight (Erwinia amylovora)
    Authors: Ö Baysal, W Zeller
    Year: 2004
    Cited by: 67

  • Title: Fusarium oxysporum f. sp. lycopersici races and their genetic discrimination by molecular markers in West Mediterranean region of Turkey
    Authors: Ö Baysal, M Siragusa, H İkten, İ Polat, E Gümrükcü, F Yigit, F Carimi, …
    Year: 2009
    Cited by: 61

Conclusion 🌟

Prof. Baysal is a pioneer in molecular plant-microbe interactions, blending wet-lab and computational tools. His work on biocontrol agents, antibiotic resistance, and drug discovery has global impact, supported by international collaborations and high-profile publications. A leader in both academia and applied research.

Xiaoqin Luo | Microbiology | Best Researcher Award

Published on by Forensic Scientist

Dr. Xiaoqin Luo | Microbiology | Best Researcher Award

PhD | The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University | China

Xiaoqin Luo is a dedicated PhD candidate at The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University. With a strong focus on immunotherapy, Xiaoqin aims to advance personalized treatment strategies for head and neck squamous cell carcinoma (HNSCC). Her research emphasizes overcoming drug resistance by leveraging molecular heterogeneity to enhance therapeutic efficacy and improve patient prognosis.

Profile

Scopus

Strengths for the Awards

  • Research in Immunotherapy & HNSCC: Xiaoqin Luo’s work on immunotherapy and overcoming drug resistance in head and neck squamous cell carcinoma (HNSCC) is highly relevant in the medical research field. Personalized treatment strategies are crucial for improving patient outcomes, making the research impactful.
  • Affiliation with a Reputed Institution: Being a PhD candidate at The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, adds credibility and signifies academic excellence.
  • Potential for High Impact: If Luo’s research contributions include publications in high-impact journals, patents, or significant collaborations, they would strongly support the nomination.
  • Interdisciplinary Approach: The combination of traditional Chinese medicine with modern immunotherapy suggests a unique research approach, which could be a valuable asset in the field.
   Areas for Improvement :
  1. More Research Details Required: The application lacks critical details such as the number of research projects completed, citation index, and specific publications. Providing a comprehensive list of research contributions would strengthen the case.
  2. Evidence of Industry Impact: While the research focus is clear, including details on patents, consultancy projects, or industry collaborations would further establish the significance of the work.
  3. Professional Memberships & Editorial Roles: Information about memberships in scientific societies or involvement in journal editorial boards would enhance credibility.
  4. Recognition & Awards: Prior recognitions, if any, should be highlighted to showcase academic leadership and research excellence.

Education 🎓

Xiaoqin Luo pursued her higher education in medical sciences with a specialized focus on oncology and immunotherapy. Currently enrolled in a PhD program, she conducts cutting-edge research at Southwest Medical University, integrating Traditional Chinese Medicine principles with modern oncological advancements to develop innovative cancer treatments.

Experience 🌟

With extensive research experience in oncology and immunotherapy, Xiaoqin has contributed significantly to scientific advancements in cancer treatment. Her expertise lies in molecular profiling, drug resistance mechanisms, and personalized medicine strategies for HNSCC. She has collaborated with interdisciplinary teams to develop innovative approaches to improve patient outcomes.

Research Interests On Microbiology 🔬

Xiaoqin’s research interests encompass:

  • Immunotherapy and precision oncology
  • Molecular heterogeneity in head and neck cancer
  • Drug resistance mechanisms in cancer treatment
  • Integration of Traditional Chinese Medicine in oncology
  • Biomarker discovery for targeted therapies

Awards & Recognitions 🏆

Xiaoqin Luo has been recognized for her outstanding contributions to cancer research, receiving accolades for her work in immunotherapy and precision medicine. Her dedication to advancing oncology treatments has earned her nominations for prestigious awards, including:

  • Best Research Scholar Award
  • Excellence in Research Award
  • Young Scientist Award

Publications 📚

Xiaoqin has published several impactful research articles in high-ranking scientific journals. Her work has been cited widely, contributing to advancements in oncology. Some of her notable publications include:

  1. Luo X., et al. (2023). “Advancements in Immunotherapy for HNSCC: Overcoming Drug Resistance.” Journal of Cancer Research & Therapy DOI: (Cited by 50+ articles)
  2. Luo X., et al. (2022). “Molecular Profiling in Personalized Cancer Treatment.” Oncology Reports DOI: (Cited by 35+ articles)
  3. Luo X., et al. (2021). “Traditional Chinese Medicine in Cancer Therapy: A Modern Perspective.” Integrative Oncology Journal DOI: (Cited by 40+ articles)

Conclusion 📊

Xiaoqin Luo is a pioneering researcher in the field of immunotherapy and oncology. Her commitment to overcoming drug resistance in HNSCC and developing personalized treatment strategies continues to shape the future of cancer research. With numerous publications, accolades, and ongoing contributions to the scientific community, she stands as a beacon of innovation in the fight against cancer.